title: Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: progress pathology report of the Italian PROSIT study.
abstract: OBJECTIVE
  To compare the pathologic stage and surgical margin status in patients undergoing either immediate radical prostatectomy or surgery preceded by 3 or 6 months of neoadjuvant hormonal treatment (NHT) in a prospective, randomized study.
  
  
  METHODS
  Four hundred thirty-one men with prostate cancer were enrolled in the Italian randomized prospective PROSIT study. The whole-mount sectioning technique was used. By May 1999, the reviewing pathologist had evaluated 303 specimens. One hundred seven patients were untreated before radical prostatectomy was performed, and 114 and 82 patients had been treated for 3 and 6 months, respectively, with complete androgen blockade.
  
  
  RESULTS
  Pathologic organ-confined disease was found in 63.1% of patients with clinical Stage B disease treated with 6 months of NHT versus 61.0% after 3 months of NHT and 37.5% after immediate surgery. Among patients with clinical Stage C tumors, pathologic staging found organ-confined disease in 62.5%, 32.1%, and 11.1% of patients after 6 months of NHT, 3 months of NHT, and immediate surgery, respectively. Three months of NHT produced a significant increase in negative margins both in patients with clinical Stage B and C disease, but the addition of another 3 months of treatment did not significantly improve this result. A lower degree of benefit was observed in patients with clinical Stage C tumors.
  
  
  CONCLUSIONS
  This study shows that complete androgen blockade before surgery is beneficial in men with clinical Stage B disease. The effects are more pronounced after 6 months of NHT than after 3 months.
authors.affiliation: Division of Urology, Ospedale di Circolo e Fondazione Macchi, Varese, Italy.
authors.forename: A V
authors.initials: AV
authors.lastname: Bono
authors.forename: F
authors.initials: F
authors.lastname: Pagano
authors.forename: R
authors.initials: R
authors.lastname: Montironi
authors.forename: F
authors.initials: F
authors.lastname: Zattoni
authors.forename: A
authors.initials: A
authors.lastname: Manganelli
authors.forename: F P
authors.initials: FP
authors.lastname: Selvaggi
authors.forename: G
authors.initials: G
authors.lastname: Comeri
authors.forename: G
authors.initials: G
authors.lastname: Fiaccavento
authors.forename: S
authors.initials: S
authors.lastname: Guazzieri
authors.forename: C
authors.initials: C
authors.lastname: Selli
authors.forename: A
authors.initials: A
authors.lastname: Lembo
authors.forename: S
authors.initials: S
authors.lastname: Cosciani-Cunico
authors.forename: D
authors.initials: D
authors.lastname: Potenzoni
authors.forename: G
authors.initials: G
authors.lastname: Muto
authors.forename: L
authors.initials: L
authors.lastname: Diamanti
authors.forename: A
authors.initials: A
authors.lastname: Santinelli
authors.forename: R
authors.initials: R
authors.lastname: Mazzucchelli
authors.forename: T
authors.initials: T
authors.lastname: Prayer-Galletti
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018365:Neoplasm, Residual; D011446:Prospective Studies; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D013997:Time Factors
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal